You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 52 No. 10, October 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Articles
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Plasma Haloperidol Levels and Clinical Effects in Schizophrenia and Schizoaffective Disorder

Jan Volavka, MD, PhD; Thomas B. Cooper, MA; Pal Czobor, PhD; Morris Meisner, PhD

Arch Gen Psychiatry. 1995;52(10):837-845.


Abstract

Background
Plasma haloperidol levels between 5 and 11 ng/mL may be clinically optimal for acutely exacerbated schizophrenia, but the evidence for this therapeutic window has been inconsistent.

Methods
Haloperidol was administered in a doubleblind manner during two consecutive 3-week experimental periods to 65 patients with acutely exacerbated schizophrenia or schizoaffective disorder. Two plasma levels were targeted: "low" (2 ng/mL) and "moderate" (10 ng/mL). The subjects were randomly assigned to four treatment sequences (low-low, low-moderate, moderate-moderate, or moderate-low).

Results
In the first 3 weeks, the antipsychotic efficacy of haloperidol increased with plasma levels up to approximately 12 ng/mL. In the second 3 weeks, decrease of plasma levels reduced negative symptoms.

Conclusion
For most patients, plasma levels not exceeding 12 ng/mL yield the best results in the first 3 weeks of treatment. Subsequent lowering of the plasma levels may improve negative symptoms.



Author Affiliations

From the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, and the Department of Psychiatry, New York (NY) University.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low dose typical antipsychotics - a brief evaluation
Taylor
Psychiatr. Bull. 2000;24:465-468.
FULL TEXT  

Persistence of Haloperidol in Human Brain Tissue
Kornhuber et al.
Am. J. Psychiatry 1999;156:885-890.
ABSTRACT | FULL TEXT  

Haloperidol Plasma Levels and Dose Optimization
Coryell et al.
Am. J. Psychiatry 1998;155:48-53.
ABSTRACT | FULL TEXT  

The Relationship Between Plasma Haloperidol Concentrations and Clinical Results
Palao et al.
Arch Gen Psychiatry 1996;53:1167-1168.
ABSTRACT  

The Relationship Between Plasma Haloperidol Concentrations and Clinical Results-Reply
Volavka et al.
Arch Gen Psychiatry 1996;53:1168-1169.
ABSTRACT  

Haloperidol Plasma Level Predicts Antipsychotic Efficacy in Schizophrenia
JWatch Psychiatry 1995;1995:9-9.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.